# Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

> **NCT02012231** · PHASE1 · TERMINATED · sponsor: **Fore Biotherapeutics** · enrollment: 5 (actual)

## Conditions studied

- Melanoma
- Thyroid Cancer
- Colorectal Cancer
- Non-small Cell Lung Cancer
- Cholangiocarcinoma
- Histiocytosis
- Hairy Cell Leukemia

## Interventions

- **DRUG:** PLX8394

## Key facts

- **NCT ID:** NCT02012231
- **Lead sponsor:** Fore Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2014-09
- **Final completion:** 2015-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02012231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02012231, "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02012231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*